Bayer AG To Inject $700 Million In Hemophilia A Drugs

Published: Mar 11, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer HealthCare and Kythera announced that Bayer will sell back to Kythera commercial rights to ATX-101 outside of the United States and Canada. In 2010, Bayer licensed these rights from Kythera. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin). Under the new agreement, Bayer will receive $ 33 million in Kythera common stock, plus a $ 51 million promissory note, payable no later than 2024 from KYTHERA. Bayer is also eligible to receive certain long-term sales milestone payments on annual sales outside of the United States and Canada.

Help employers find you! Check out all the jobs and post your resume.

Back to news